Why this matters to buyers
Buyers in the pharmaceutical sector may face a longer timeline for supply chain adjustments but could see a gradual shift in sourcing locations for generic drugs, potentially affecting costs and lead times.
Recommended buyer actions
- Assess the impact of potential reshoring on the cost and availability of generic drug inputs.
- Engage with current suppliers to understand their transition plans in response to the proposal.
Original source context
The president’s most recent tariff proposal gives pharma more time to transition its global supply chain and reshore generic drug production.
Read the original report · Supply Chain Dive